» Articles » PMID: 19585610

Keratin Variants Are Overrepresented in Primary Biliary Cirrhosis and Associate with Disease Severity

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2009 Jul 9
PMID 19585610
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Keratins (K) 8 and 18 variants predispose carriers to the development of end-stage liver disease and patients with chronic hepatitis C to disease progression. Hepatocytes express K8/K18, whereas biliary epithelia express K8/K18/K19. K8-null mice, which are predisposed to liver injury, spontaneously develop anti-mitochondrial antibodies (AMA) and have altered hepatocyte mitochondrial size and function. There is no known association of K19 with human disease and no known association of K8/K18/K19 with human autoimmune liver disease. We tested the hypothesis that K8/K18/K19 variants associate with primary biliary cirrhosis (PBC), an autoimmune cholestatic liver disease characterized by the presence of serum AMA. In doing so, we analyzed the entire exonic regions of K8/K18/K19 in 201 Italian patients and 200 control blood bank donors. Five disease-associated keratin heterozygous variants were identified in patients versus controls (K8 G62C/R341H/V380I, K18 R411H, and K19 G17S). Four variants were novel and included K19 G17S/V229M/N184N and K18 R411H. Overall, heterozygous disease-associated keratin variants were found in 17 of 201 (8.5%) PBC patients and 4 of 200 (2%) blood bank donors (P < 0.004, odds ratio = 4.53, 95% confidence interval = 1.5-13.7). Of the K19 variants, K19 G17S was found in three patients but not in controls and all K8 R341H (eight patients and three controls) associated with concurrent presence of the previously described intronic K8 IVS7+10delC deletion. Notably, keratin variants associated with disease severity (12.4% variants in Ludwig stage III/IV versus 4.2% in stages I/II; P < 0.04, odds ratio = 3.25, 95% confidence interval = 1.02-10.40), but not with the presence of AMA.

Conclusion: K8/K18/K19 variants are overrepresented in Italian PBC patients and associate with liver disease progression. Therefore, we hypothesize that K8/K18/K19 variants may serve as genetic modifiers in PBC.

Citing Articles

The relationship between keratin 18 and epithelial-derived tumors: as a diagnostic marker, prognostic marker, and its role in tumorigenesis.

Yan J, Yang A, Tu S Front Oncol. 2024; 14:1445978.

PMID: 39502314 PMC: 11534658. DOI: 10.3389/fonc.2024.1445978.


Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma.

Lim Y, Ku N Int J Mol Sci. 2021; 22(12).

PMID: 34203895 PMC: 8232640. DOI: 10.3390/ijms22126401.


Liver disease-associated keratin 8 and 18 mutations modulate keratin acetylation and methylation.

Jang K, Yoon H, Lee J, Yi H, Park S, Lee S FASEB J. 2019; 33(8):9030-9043.

PMID: 31199680 PMC: 6988862. DOI: 10.1096/fj.201800263RR.


Plasma Levels of K18 Fragments Do Not Correlate with Alcoholic Liver Fibrosis.

Schlossberger V, Worni M, Kihm C, Montani M, Datz C, Hampe J Gut Liver. 2018; 13(1):77-82.

PMID: 29976035 PMC: 6346996. DOI: 10.5009/gnl18037.


Intermediate filament proteins of digestive organs: physiology and pathophysiology.

Omary M Am J Physiol Gastrointest Liver Physiol. 2017; 312(6):G628-G634.

PMID: 28360031 PMC: 5495917. DOI: 10.1152/ajpgi.00455.2016.


References
1.
Strnad P, Lienau T, Tao G, Ku N, Magin T, Omary M . Denaturing temperature selection may underestimate keratin mutation detection by DHPLC. Hum Mutat. 2006; 27(5):444-52. DOI: 10.1002/humu.20311. View

2.
Omary M, Coulombe P, McLean W . Intermediate filament proteins and their associated diseases. N Engl J Med. 2004; 351(20):2087-100. DOI: 10.1056/NEJMra040319. View

3.
Szeverenyi I, Cassidy A, Chung C, Lee B, Common J, Ogg S . The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat. 2007; 29(3):351-60. DOI: 10.1002/humu.20652. View

4.
Gross R, Odin J . Recent advances in the epidemiology of primary biliary cirrhosis. Clin Liver Dis. 2008; 12(2):289-303. DOI: 10.1016/j.cld.2008.02.001. View

5.
Mendes F, Kim W, Pedersen R, Therneau T, Lindor K . Mortality attributable to cholestatic liver disease in the United States. Hepatology. 2008; 47(4):1241-7. DOI: 10.1002/hep.22178. View